Latest Insys Therapeutics Inc (INSY) Headlines
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Has Insys Run Too Far Too Fast?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Few investments have paid off as handsomely as Insys this past year. The company, which gets most of its sales from breakthrough pain treatment Subsys, has soared more than 700% in the past year. The excitement surrounding Insys has come as...
INSYS Therapeutics (INSY) Soars: Stock Adds 21.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:39AM CST
INSYS Therapeutics, Inc. was a big mover last session, as its shares rose just nearly 22% on the day.
Insys Therapeutics: Today's Big Biotech Winner
David Williamson, The Motley Fool - Motley Fool - Tue Mar 04, 6:52PM CST
Shares of Insys Therapeutics rose 20% today, after the company posted strong second-quarter results for its cancer-related pain medicine, Subsys. After operating at a loss last year, the 38% sales growth of the drug this year helped propel Insys...
Insys Q4 Earnings Beat Street; Stock Hits High
at Investor's Business Daily - Tue Mar 04, 2:44PM CST
Biotech Insys Therapeutics (INSY) soundly beat analysts' Q4 estimates and announced a stock split Tuesday, sending shares soaring more than 20% to a new high on the stock market today. The company's revenue totaled $40 million in the quarter vs. just...
Stocks Rally As Ukraine Fears Ebb; China Names Lead
at Investor's Business Daily - Tue Mar 04, 2:09PM CST
Fears of a conflict in Ukraine subsided -- at least for a day -- on Wall Street as stocks raced out of the gate and held strong gains with a little over one hour remaining in the session. The Nasdaq gained 1.6%, good for another 52-week high. The S&P...
Why Insys Therapeutics, Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 12:23PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Insys Therapeutics , a biopharmaceutical...
Insys Therapeutics Reports Fourth Quarter and Year End 2013 Results
Marketwire - Tue Mar 04, 5:50AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company with a focus on supportive care products for cancer patients, today announced its financial results for the three- and twelve- month periods ended December 31, 2013. Fourth quarter 2013 highlights include:
Ukraine Unrest Sparks Selling But Some Biotechs Firm Up
at Investor's Business Daily - Mon Mar 03, 3:22PM CST
Major averages suffered a setback Monday with closes near lows and losses close to 1%. It's been a while since geopolitical concerns unnerved the market, but Russia's military presence in Ukraine continued to take center stage. The Dow Jones...
Insys Set To Report Q4 Earnings With Stock Surging
at Investor's Business Daily - Sat Mar 01, 7:32AM CST
Insys Therapeutics (INSY) is set to report fourth-quarter earnings on a roll, with an upwardly mobile stock price and fewer concerns about the future of its top-selling product. The Chandler, Ariz.-based company develops supportive care products for...
Insys Therapeutics Reports Dismissal of Stockholder Class Action Lawsuit
Marketwire - Fri Feb 21, 6:00AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company with a focus on supportive care products for cancer patients, today announced that the previously reported stockholder class action lawsuit (Hillier v. Insys Therapeutics Incorporated et al) that had been filed against the Company and certain of its officers and directors in U.S. District Court for the District of Arizona was on February 20, 2014, voluntarily dismissed by the plaintiff and thereafter terminated by the court. No payment or consideration of any kind was made by any of the defendants in connection with the dismissal.
Commit To Purchase Insys Therapeutics At $45, Earn 25.4% Annualized Using Options
at The Street - Tue Feb 18, 10:27AM CST
Investors eyeing a purchase of Insys Therapeutics stock, but cautious about paying the going market price of $57.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013 Report
M2 - Tue Feb 18, 2:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/ssk4w8/adrenocortical) has announced the addition of the "Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013" report to their offering. 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Scope - A snapshot of the global therapeutic scenario for Adrenocortical Carcinoma (Adrenal Cortex Cancer). - A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview Therapeutics Development Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis Drug Profiles axitinib - Drug Profile AT-101 - Drug Profile cintredekin besudotox - Drug Profile TKM-PLK1 - Drug Profile ATR-101 - Drug Profile Steroidogenic Factor-1 Antagonists - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Tekmira Pharmaceuticals Corp. Pfizer Inc. Insys Therapeutics, Inc. Ascenta Therapeutics, Inc. Orphagen Pharmaceuticals, Inc. Atterocor, Inc. For more information visit http://www.researchandmarkets.com/research/ss...nocortical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Insys Therapeutics to Report Fourth Quarter and Year-End 2013 Financial Results on March 4
Marketwire - Wed Feb 12, 3:30PM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that the Company will release its fourth quarter and year-end 2013 financial results on Tuesday, March 4, 2014, before the market opens.
Insys Recovers From Stock Hit Tied To Fed Probe
at Investor's Business Daily - Wed Feb 12, 12:24PM CST
Insys Therapeutics went public less than a year ago, but it has already seen the good, bad and ugly of Wall Street. The company develops supportive care products for breakthrough cancer pain. Its stock has rallied 37% this year, recovering from...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Insys Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- INSY
GlobeNewswire - Sun Feb 02, 12:00AM CST
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Insys Therapeutics, Inc. ("Insys" or the "Company") (Nasdaq:INSY) and certain of its officers. The class action, filed in United States District Court, District of Arizona, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Insys between May 1, 2013 and December 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses from Investment in Insys Therapeutics, Inc. to Contact Brower Piven Before the February 14, 2014 Lead Plaintiff Deadline
Business Wire - Fri Jan 31, 8:20PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Arizona on behalf of purchasers of Insys Therapeutics, Inc. ("Insys" or the "Company") (NasdaqGM: INSY) securities during the period between May 1, 2013 and December 12, 2013, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Insys Therapeutics, Inc. and Certain Officers -- INSY
PR Newswire - Fri Jan 17, 1:17PM CST
Pomerantz LLP has filed a class action lawsuit against Insys Therapeutics, Inc. ("Insys" or the "Company") (NASDAQ: INSY) and certain of its officers. The class action, filed in United States District Court, District of Arizona, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Insys between May 1, 2013 and December 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Insys Announces Details of Product Development Pipeline
Marketwire - Mon Jan 13, 6:00AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY) today unveiled details of its portfolio pipeline, focused on innovative supportive care and therapy products. The Company intends to file one New Drug Application (NDA) and at least three Investigational New Drug (IND) applications with the Food and Drug Administration (FDA) in 2014.
EQUITY ALERT: Rosen Law Firm Announces Class Action Lawsuit Against Insys Therapeutics, Inc. -- INSY
GlobeNewswire - Sat Jan 11, 3:26PM CST
The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of purchasers of Insys Therapeutics, Inc. (Nasdaq:INSY) securities during the period between May 1, 2013 and December 12, 2013, inclusive, seeking to recover damages for violations of the federal securities laws.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Has Insys Run Too Far Too Fast?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Few investments have paid off as handsomely as Insys this past year. The company, which gets most of its sales from breakthrough pain treatment Subsys, has soared more than 700% in the past year. The excitement surrounding Insys has come as...
INSYS Therapeutics (INSY) Soars: Stock Adds 21.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:39AM CST
INSYS Therapeutics, Inc. was a big mover last session, as its shares rose just nearly 22% on the day.
Insys Therapeutics: Today's Big Biotech Winner
David Williamson, The Motley Fool - Motley Fool - Tue Mar 04, 6:52PM CST
Shares of Insys Therapeutics rose 20% today, after the company posted strong second-quarter results for its cancer-related pain medicine, Subsys. After operating at a loss last year, the 38% sales growth of the drug this year helped propel Insys...
Insys Q4 Earnings Beat Street; Stock Hits High
at Investor's Business Daily - Tue Mar 04, 2:44PM CST
Biotech Insys Therapeutics (INSY) soundly beat analysts' Q4 estimates and announced a stock split Tuesday, sending shares soaring more than 20% to a new high on the stock market today. The company's revenue totaled $40 million in the quarter vs. just...
Stocks Rally As Ukraine Fears Ebb; China Names Lead
at Investor's Business Daily - Tue Mar 04, 2:09PM CST
Fears of a conflict in Ukraine subsided -- at least for a day -- on Wall Street as stocks raced out of the gate and held strong gains with a little over one hour remaining in the session. The Nasdaq gained 1.6%, good for another 52-week high. The S&P...
Why Insys Therapeutics, Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 12:23PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Insys Therapeutics , a biopharmaceutical...
Insys Therapeutics Reports Fourth Quarter and Year End 2013 Results
Marketwire - Tue Mar 04, 5:50AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company with a focus on supportive care products for cancer patients, today announced its financial results for the three- and twelve- month periods ended December 31, 2013. Fourth quarter 2013 highlights include:
Ukraine Unrest Sparks Selling But Some Biotechs Firm Up
at Investor's Business Daily - Mon Mar 03, 3:22PM CST
Major averages suffered a setback Monday with closes near lows and losses close to 1%. It's been a while since geopolitical concerns unnerved the market, but Russia's military presence in Ukraine continued to take center stage. The Dow Jones...
Insys Set To Report Q4 Earnings With Stock Surging
at Investor's Business Daily - Sat Mar 01, 7:32AM CST
Insys Therapeutics (INSY) is set to report fourth-quarter earnings on a roll, with an upwardly mobile stock price and fewer concerns about the future of its top-selling product. The Chandler, Ariz.-based company develops supportive care products for...
Insys Therapeutics Reports Dismissal of Stockholder Class Action Lawsuit
Marketwire - Fri Feb 21, 6:00AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company with a focus on supportive care products for cancer patients, today announced that the previously reported stockholder class action lawsuit (Hillier v. Insys Therapeutics Incorporated et al) that had been filed against the Company and certain of its officers and directors in U.S. District Court for the District of Arizona was on February 20, 2014, voluntarily dismissed by the plaintiff and thereafter terminated by the court. No payment or consideration of any kind was made by any of the defendants in connection with the dismissal.
Commit To Purchase Insys Therapeutics At $45, Earn 25.4% Annualized Using Options
at The Street - Tue Feb 18, 10:27AM CST
Investors eyeing a purchase of Insys Therapeutics stock, but cautious about paying the going market price of $57.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013 Report
M2 - Tue Feb 18, 2:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/ssk4w8/adrenocortical) has announced the addition of the "Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013" report to their offering. 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Scope - A snapshot of the global therapeutic scenario for Adrenocortical Carcinoma (Adrenal Cortex Cancer). - A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview Therapeutics Development Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis Drug Profiles axitinib - Drug Profile AT-101 - Drug Profile cintredekin besudotox - Drug Profile TKM-PLK1 - Drug Profile ATR-101 - Drug Profile Steroidogenic Factor-1 Antagonists - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Tekmira Pharmaceuticals Corp. Pfizer Inc. Insys Therapeutics, Inc. Ascenta Therapeutics, Inc. Orphagen Pharmaceuticals, Inc. Atterocor, Inc. For more information visit http://www.researchandmarkets.com/research/ss...nocortical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Insys Therapeutics to Report Fourth Quarter and Year-End 2013 Financial Results on March 4
Marketwire - Wed Feb 12, 3:30PM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that the Company will release its fourth quarter and year-end 2013 financial results on Tuesday, March 4, 2014, before the market opens.
Insys Recovers From Stock Hit Tied To Fed Probe
at Investor's Business Daily - Wed Feb 12, 12:24PM CST
Insys Therapeutics went public less than a year ago, but it has already seen the good, bad and ugly of Wall Street. The company develops supportive care products for breakthrough cancer pain. Its stock has rallied 37% this year, recovering from...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Insys Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- INSY
GlobeNewswire - Sun Feb 02, 12:00AM CST
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Insys Therapeutics, Inc. ("Insys" or the "Company") (Nasdaq:INSY) and certain of its officers. The class action, filed in United States District Court, District of Arizona, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Insys between May 1, 2013 and December 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses from Investment in Insys Therapeutics, Inc. to Contact Brower Piven Before the February 14, 2014 Lead Plaintiff Deadline
Business Wire - Fri Jan 31, 8:20PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Arizona on behalf of purchasers of Insys Therapeutics, Inc. ("Insys" or the "Company") (NasdaqGM: INSY) securities during the period between May 1, 2013 and December 12, 2013, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Insys Therapeutics, Inc. and Certain Officers -- INSY
PR Newswire - Fri Jan 17, 1:17PM CST
Pomerantz LLP has filed a class action lawsuit against Insys Therapeutics, Inc. ("Insys" or the "Company") (NASDAQ: INSY) and certain of its officers. The class action, filed in United States District Court, District of Arizona, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Insys between May 1, 2013 and December 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Insys Announces Details of Product Development Pipeline
Marketwire - Mon Jan 13, 6:00AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY) today unveiled details of its portfolio pipeline, focused on innovative supportive care and therapy products. The Company intends to file one New Drug Application (NDA) and at least three Investigational New Drug (IND) applications with the Food and Drug Administration (FDA) in 2014.
EQUITY ALERT: Rosen Law Firm Announces Class Action Lawsuit Against Insys Therapeutics, Inc. -- INSY
GlobeNewswire - Sat Jan 11, 3:26PM CST
The Rosen Law Firm, P.A. announces that a class action lawsuit has been filed on behalf of purchasers of Insys Therapeutics, Inc. (Nasdaq:INSY) securities during the period between May 1, 2013 and December 12, 2013, inclusive, seeking to recover damages for violations of the federal securities laws.
